Is Syncom Formul. overvalued or undervalued?

As of 13 November 2025, the valuation grade for Syncom Formulations has moved from expensive to very expensive. This indicates a significant shift in the perception of the company's valuation, suggesting that it is currently overvalued. The key ratios reflect this assessment, with a PE Ratio of 25.08, an EV to EBITDA of 22.41, and a Price to Book Value of 4.62, all of which are elevated compared to industry norms.
In comparison to its peers, Syncom Formulations' valuation metrics stand out unfavorably. For instance, Sun Pharma has a PE Ratio of 36.15, while Divi's Lab shows an even higher valuation at 70.4. In contrast, Cipla, which is rated as attractive, has a much lower PE Ratio of 22.65, indicating that Syncom Formulations is not only overvalued but also less competitive in terms of valuation relative to its peers. Additionally, while Syncom has shown strong returns over the long term, its recent performance has lagged behind the Sensex, with a year-to-date return of -15.95% compared to the Sensex's 8.11%.